Cathay Biotech Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Xiucai Liu

Chief Executive Officer (CEO)

CN¥4.1m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality Issues

Nov 07

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Oct 22

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Jun 19

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

May 28

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

May 07

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

May 06

CEO

Xiucai Liu (67 yo)

5.3yrs

Permanencia

CN¥4,065,600

Compensación

Dr. Xiucai Liu has been Chairman of Cathay Industrial Biotech, Ltd. (formerly known as Cathay Biotech Inc.) since April 2006 and serves as its Chief Executive Officer. Dr. Liu serves as Chairman and Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Xiucai Liu	Chairman & CEO	5.3yrs	CN¥4.07m	sin datos
Chen Yang	VP, Core Technician & COO	2.8yrs	CN¥1.00m	sin datos
Huiqing Zang	Vice President	no data	CN¥1.06m	sin datos
Yijun Du	Vice President	5.3yrs	CN¥1.26m	sin datos
Hong Guang Zhang	Vice President	5.3yrs	CN¥1.05m	0.0010% CN¥ 263.6k

5.3yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 688065 es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xiucai Liu	Chairman & CEO	5.3yrs	CN¥4.07m	sin datos
Huiqing Zang	Vice President	5.3yrs	CN¥1.06m	sin datos
William Robert Keller	Director	5.3yrs	CN¥535.60k	sin datos
Faqin Lu	Independent Director	5.3yrs	CN¥100.00k	sin datos
Bing Zhang	Independent Director	5.3yrs	CN¥100.00k	sin datos
Guohua Zhang	Chairman of the Supervisory Board	5.3yrs	sin datos	sin datos
Li Pan	Supervisor	5.3yrs	sin datos	sin datos
Xin Liu	Supervisor	5.3yrs	sin datos	sin datos
Xiang Yang Wu	Independent Director	2.3yrs	CN¥100.00k	sin datos

5.3yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 688065 se considera experimentada (5.3 años de antigüedad promedio).

Cathay Biotech Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality Issues

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)

Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 23%

Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)

Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 21%

New major risk - Revenue and earnings growth

Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)

Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.

Price target increased by 8.3% to CN¥67.18

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)

Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023

Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group Limited

Full year 2022 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)

Less than half of directors are independent

Cathay Biotech Inc. announced that it has received $28 million in funding from Eight Roads Ventures, Sequoia China Investment Management LLP, Source Code Capital, Bits x Bites

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in 3Q 2021)

Price target increased to CN¥91.82

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.34 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥1.46 (vs CN¥1.18 in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.23 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.32 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.18 (vs CN¥1.32 in FY 2019)

Cathay Biotech Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥82.67

New 90-day low: CN¥88.56

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad